Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
78.2M
-
Number of holders
-
47
-
Total 13F shares, excl. options
-
51.5M
-
Shares change
-
+1.4M
-
Total reported value, excl. options
-
$113M
-
Value change
-
+$3.03M
-
Number of buys
-
31
-
Number of sells
-
-6
-
Price
-
$2.19
Significant Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q1 2025
50 filings reported holding IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value as of Q1 2025.
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) has 47 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.5M shares
of 78.2M outstanding shares and own 65.84% of the company stock.
Largest 10 shareholders include Sands Capital Ventures, LLC (11M shares), Soleus Capital Management, L.P. (6.33M shares), Fairmount Funds Management LLC (6.13M shares), PERCEPTIVE ADVISORS LLC (5.93M shares), COMMODORE CAPITAL LP (5.34M shares), ADAR1 Capital Management, LLC (5.12M shares), VANGUARD GROUP INC (2.85M shares), Nantahala Capital Management, LLC (2.19M shares), Blackstone Inc. (2.07M shares), and Stonepine Capital Management, LLC (915K shares).
This table shows the top 47 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.